These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Antimicrobial drug use and macrolide-resistant Streptococcus pyogenes, Belgium. Van Heirstraeten L; Coenen S; Lammens C; Hens N; Goossens H; Malhotra-Kumar S Emerg Infect Dis; 2012 Sep; 18(9):1515-8. PubMed ID: 22932671 [TBL] [Abstract][Full Text] [Related]
6. Macrolide- and telithromycin-resistant Streptococcus pyogenes, Belgium, 1999-2003. Malhotra-Kumar S; Lammens C; Chapelle S; Wijdooghe M; Piessens J; Van Herck K; Goossens H Emerg Infect Dis; 2005 Jun; 11(6):939-42. PubMed ID: 15963292 [TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. Farrell DJ; Morrissey I; Bakker S; Felmingham D J Antimicrob Chemother; 2002 Sep; 50 Suppl S1():39-47. PubMed ID: 12239227 [TBL] [Abstract][Full Text] [Related]
8. Circulating serotypes and antimicrobial sensitivity of Streptococcus pyogenes isolates from children in Cyprus. Koliou M; Ioannou Y; Efstratiou A; Hannidou N; Pieri V; Alexandrou M; Soteriades ES Clin Microbiol Infect; 2007 Jun; 13(6):645-7. PubMed ID: 17378928 [TBL] [Abstract][Full Text] [Related]
9. Molecular analysis of Streptococcus pyogenes macrolide resistance of paediatric isolates during a 7 year period (2007-13). Michos A; Koutouzi FI; Tsakris A; Chatzichristou P; Koutouzis EI; Daikos GL; Stathi A; Syriopoulou VP J Antimicrob Chemother; 2016 Aug; 71(8):2113-7. PubMed ID: 27118782 [TBL] [Abstract][Full Text] [Related]
10. mef(A) is the predominant macrolide resistance determinant in Streptococcus pneumoniae and Streptococcus pyogenes in Germany. Bley C; van der Linden M; Reinert RR Int J Antimicrob Agents; 2011 May; 37(5):425-31. PubMed ID: 21419605 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of macrolide and tetracycline resistance mechanisms in Streptococcus pyogenes isolates and in vitro susceptibility to telithromycin. Betriu C; Culebras E; Redondo M; Rodríguez-Avial I; Gómez M; Boloix A; Picazo JJ J Antimicrob Chemother; 2002 Sep; 50(3):436-8. PubMed ID: 12205076 [No Abstract] [Full Text] [Related]
12. Prevalence of macrolide resistance in Streptococcus pyogenes collected in Serbia. Pavlovic L; Grego E; Sipetic-Grujicic S Jpn J Infect Dis; 2010 Jul; 63(4):275-6. PubMed ID: 20657068 [TBL] [Abstract][Full Text] [Related]
13. [Update on antibiotic sensitive Streptococcus pyogenes in a pediatric population]. Gené A; González-Cuevas A; Muñoz C; Luaces C; Latorre C Enferm Infecc Microbiol Clin; 2000 Mar; 18(3):144-5. PubMed ID: 10905020 [No Abstract] [Full Text] [Related]
14. Susceptibility of Streptococcus pyogenes to two macrolides in northern Israel. Sakran W; Raz R; Chazan B; Koren A; Colodner R Int J Antimicrob Agents; 2004 May; 23(5):517-9. PubMed ID: 15120735 [TBL] [Abstract][Full Text] [Related]
15. Prevalence of Streptococcus invasive locus (sil) and its relationship with macrolide resistance among group A Streptococcus strains. Billal DS; Hotomi M; Shimada J; Fujihara K; Ubukata K; Sugita R; Yamanaka N J Clin Microbiol; 2008 Apr; 46(4):1563-4. PubMed ID: 18287313 [No Abstract] [Full Text] [Related]
16. Resistance to macrolides in clinical isolates of Streptococcus pyogenes due to ribosomal mutations. Malbruny B; Nagai K; Coquemont M; Bozdogan B; Andrasevic AT; Hupkova H; Leclercq R; Appelbaum PC J Antimicrob Chemother; 2002 Jun; 49(6):935-9. PubMed ID: 12039885 [TBL] [Abstract][Full Text] [Related]
17. Current status of antimicrobial susceptibility of clinical isolates of Streptococcus pyogenes in Japan: report of a countrywide surveillance study. Hotomi M; Billal DS; Shimada J; Yamauchi K; Fujihara K; Yamanaka N; J Infect Chemother; 2005 Feb; 11(1):48-51. PubMed ID: 15729489 [TBL] [Abstract][Full Text] [Related]
18. [Macrolides in the treatment of streptococcal pharyngitis: not all effective]. Alós JI Med Clin (Barc); 1999 Jan; 112(1):18-9. PubMed ID: 10027181 [No Abstract] [Full Text] [Related]
19. Development of macrolide-resistance and comparative activity of telithromycin in streptococci in Austria, 1996-2002. Buxbaum A; Forsthuber S; Sauermann R; Gattringer R; Graninger W; Georgopoulos A; Int J Antimicrob Agents; 2004 Oct; 24(4):397-400. PubMed ID: 15380268 [TBL] [Abstract][Full Text] [Related]